Navigation Links
OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Date:6/26/2012

SAN DIEGO, June 26, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), a company developing the OncoSec Medical System (OMS) ElectroOncology therapies to treat advanced-stage solid tumors, announced that Dr. Adil Daud, principal investigator, presented preliminary enrollment and safety data at the Second European Post-Chicago Melanoma Meeting in Munich, Germany for the company's on-going Phase II metastatic melanoma clinical trial, OMS-I100.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

To date, OMS-I100, a Phase II open-label, multi-center clinical trial investigating the safety and efficacy of plasmid interleukin-12 (DNA IL-12) with electroporation, has completed approximately 50 percent of enrollment. Based on currently available safety data, no grade three or higher adverse events related to the treatment have been reported, and most reported adverse events were treatable and transient.

Dr. Adil Daud said, "Interest in this study has been encouraging, and we expect to complete enrollment before the end of this year. We look forward to continuing follow-up of the patients that have been treated in order to measure any indication of a systemic immune response using DNA IL-12 and electroporation."

Punit Dhillon, President and CEO of OncoSec said, "Although preliminary, these results may validate the safety and tolerability of DNA IL-12 and electroporation that was demonstrated in the Phase I study." Mr. Dhillon added, "Following the design and implementation of our clinical development plan in 2011, we are pleased with the rapid enrollment for this study since initiation in February 2012, and believe it supports the adoption of the technology through our collaboration with leading academic institutions. We look forward to presenting an interim analysis of the clinical and immune response for this study late
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
4. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
5. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
6. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
7. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
8. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
9. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
10. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
11. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ... year ended December 31, 2014 on March 9, 2015. The Company ... on Thursday, March 12, 2015, at 5:00 pm ET. The call ...   , , , LIVE CALL:  ... code 92238648. , , , , ...
(Date:3/1/2015)... Telbec/ -   Ergoresearch Ltd (TSXV: ERG) – based ... the « Équilibre, orthèses et biomécanique» banner  – ... December 31, 2014. All dollar amounts in the present ... for the second quarter of fiscal year 2015 ended ... 8,8 % compared to revenues of $ 4 489 330 ...
(Date:3/1/2015)... 2015  USPlabs has notified the Food and ... that media reports saying that a company product ... February 28, 2015, the Center for Drug Evaluation ... the contamination of a dietary supplement product labeled ... as "OEP") with a prescription drug active ingredient, ...
Breaking Medicine Technology:ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 3Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 4OEP Product Is Counterfeit 2
(Date:3/1/2015)... 02, 2015 Security Life Insurance ... benefits market, announced the addition of stand-alone individual ... Vision Insurance launched today, complete with two plan ... utilize the VSP® Vision Care network encompassing a ... practice space. The PrimeStar Select Vision plan will ...
(Date:3/1/2015)... 2015 Women’s Excellence now offers ... (OAB) symptoms, such as a strong need to urinate with ... medication (anticholinergic) does not work well enough or cannot be ... another approach to targeting the source of OAB, the bladder ... and bladder muscle, blocking the signals that trigger OAB. ...
(Date:3/1/2015)... March 01, 2015 Researchers say working ... so many sheet metal workers contract malignant mesothelioma. Surviving ... report on its website. Click here to read ... Construction Research and Training monitored 17,345 sheet metal workers ... number of them died of mesothelioma or another ...
(Date:3/1/2015)... New York, NY (PRWEB) March 01, 2015 ... ) has grown substantially over the past few weeks ... Liebhard LLP are actively filing claims, the Firm announces. ... 2015 reflects 7,713 cases in the Bergen County proceeding ... Ethicon Inc., compared with a few weeks earlier, when ...
(Date:3/1/2015)... 2015 “ The Barrel Mill ” was ... which takes a look at the latest and coolest technology ... of NewsWatch and a technology expert, conducted the review and ... to drinks. , According to Home Distillation of Alcohol, it's ... Well, there’s a pretty cool product that’ll help anyone achieve ...
Breaking Medicine News(10 mins):Health News:Security Life Insurance Company Launches Individual Vision Insurance Product 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2
... ... PhD, JD, is Keynote Speaker on the Failed War on Drugs , ... Las Vegas, NV (PRWEB) September 11, 2009 -- ... Drug Policy Alliance advocating for drug reform in the United States as keynote speaker former ...
... acoustic neuromas , FRIDAY, Sept. 11 (HealthDay News) -- Last ... or the sound of a dog barking. She was 22. ... type 2 (NF2), a condition characterized by tumors in the ... cranial nerve in one ear. , The result: increasing hearing ...
... affects insulin resistance, study finds, , FRIDAY, Sept. 11 (HealthDay ... insight into type 2 diabetes, potentially leading to better treatment ... appears to be linked to diabetes, affects how the body ... published Sept. 6 in Nature Genetics . , "Most ...
... Duane Reade Holdings Inc., the largest drug store in metropolitan New ... 2009 Komen New York City Race For The Cure, the Company, ... raised $330,000 to increase awareness of breast cancer and to assist ... year that Duane Reade has proudly sponsored this momentous event, with ...
... , , MADISON, N.J. and ... (FDA) today cleared the OVA1(TM) Test, the first blood test that, ... at risk for a malignant pelvic mass. OVA1 is the first ... with high sensitivity prior to biopsy or exploratory surgery, even if ...
... , , , ... Gardasil, declined by a third this year, and three years after ... women remain unvaccinated -- despite millions spent on advertising and lobbying ... , , Michelle Steward, assistant professor of marketing ...
Cached Medicine News:Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 2Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 3Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 2Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 3Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 3Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 2Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 3Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 4Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 5Health News:HPV Vaccine Study Shows Why Few Women Getting Shots 2
... Graft, the newest vascular graft offering from ... in vascular surgical products for more than ... kinking and compression problems that can ... provides all of the benefits of a ...
... The drilling and rasping necessary in cruciate ... roughness on the bone surface. This condition, ... can damage the cruciate replacement. The GORE ... cruciate ligament reconstruction procedures. The tool functions ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
... has been designed by practicing neurophysiologists ... the ever changing and demanding medical ... data from multiple modalities, including: SSEPs ... multiple patients at multiple sites. Our ...
Medicine Products: